Bioxytran, Inc.
BIXT
$0.077
-$0.0068-8.12%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.82% | -63.52% | |||
| Depreciation & Amortization | 31.58% | -34.48% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -56.17% | 5.25% | |||
| Operating Income | 56.17% | -5.25% | |||
| Income Before Tax | 102.62% | -161.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 102.62% | -161.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 102.62% | -168.78% | |||
| EBIT | 56.17% | -5.25% | |||
| EBITDA | 56.49% | -5.49% | |||
| EPS Basic | 102.63% | -181.48% | |||
| Normalized Basic EPS | 102.11% | -43.94% | |||
| EPS Diluted | 102.63% | -181.48% | |||
| Normalized Diluted EPS | 102.11% | -43.94% | |||
| Average Basic Shares Outstanding | 0.00% | -4.40% | |||
| Average Diluted Shares Outstanding | 0.00% | -4.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||